[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"tumor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:tumor":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,32,0,25,[9,48,70,102,122,146,164,189,217,237,263,288,348,376,394,414,448,468,495,521,546,569,593,613,634],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100642041","phase-2-sbrt-lattice-pathy-100642041",false,"NCT07645261","SBRT-LATTICE-PATHY","Impact of Partial Stereotactic Body Radiotherapy in Hypoxic Segments of Large-volume Unresectable Tumors (SBRT-LATTICE-PATHY) - a Prospective Phase II Study.","Inclusion Criteria:\n\n* age =or\\> 18 years;\n* Eastern Cooperative Oncology Group (ECOG) performance status \\\u003C 2; benign and malignant tumors for which the use of radiotherapy is well established in the literature;\n* tumors =or\\> 340 cm³ or with a largest diameter =or\\> 7 cm;\n* no indication for any other type of treatment due to lack of proven clinical benefit (surgery, chemotherapy, standard radiotherapy, immunotherapy, targeted therapy, etc.);\n* Palliative Prognostic Index (PPI) =or\\\u003C 2;\n* metastatic disease in the central nervous system (CNS), if present, controlled (up to 3 metastases, each up to 1 cm);\n* up to 5 extracranial distant metastases (nodal or extranodal) =or\\\u003C 5 cm; signed Informed Consent Form (ICF).\n\nExclusion Criteria:\n\n* cases in which tumor volume and\u002For the patient's clinical condition make adequate immobilization\u002Fsimulation impossible;\n* previous local radiotherapy;\n* pregnant patients;\n* autoimmune diseases;\n* genetic instability syndromes;\n* ongoing systemic therapy;\n* renal insufficiency that prevents the use of iodinated contrast.","ALL","18 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","To assess the importance of using SBRT-LATTICE-PATHY for the radiotherapy treatment of large tumors that would be considered intractable by currently used standard techniques. In this present study, the investigators will have the possibility of combining SBRT and LATTICE techniques, incorporating the concept of hypoxic tissue irradiation, which are potential modulators of abscopal and bystander effects, performing partial punctual treatment in the vertex region, without the need for irradiation of the entire tissue volume, further improving safety in relation to possible toxicities.",[27,28,29],"Cancer (Advanced Stage)","Cancer (Solid Tumors)","Tumor",[31,32,33,34],"SBRT","LATTICE","partial irradiation","large volume tumors","RECRUITING","2026-06-08",{"date":38,"type":39},"2026-06-12","ACTUAL",{"date":41,"type":39},"2026-04-28",{"date":43,"type":21},"2027-12-31",{"name":45,"class":46},"University of Sao Paulo General Hospital","OTHER",1,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":47},"100643739","clinical-application-value-of-deep-learning-based-opportunistic-screening-for-malignant-tumors-on-routine-non-contrast-chest-abdomen-pelvis-ct-100643739","NCT07639567","Clinical Application Value of Deep Learning-Based \"Opportunistic Screening\" for Malignant Tumors on Routine Non-Contrast Chest-Abdomen-Pelvis CT","Inclusion Criteria:\n\n1. Patients with a confirmed diagnosis of the target malignancy who received treatment at our institution;\n2. Diagnostic-quality CT images without substantial metal or motion artifacts and with complete anatomical coverage of the target organ (breast, liver, kidney, or bladder);\n3. Availability of complete pre-treatment non-contrast CT imaging data.\n\nExclusion Criteria:\n\n1. Non-diagnostic image quality;\n2. Absence of a definitive reference-standard diagnosis;\n3. Incomplete clinical or imaging data.",true,{"count":56,"type":21},100000,"OBSERVATIONAL","This study aims to develop and validate a deep learning-based opportunistic multi-cancer screening system using routine non-contrast chest-abdomen-pelvis CT examinations, including CHANCE-Breast, CHANCE-Liver, CHANCE-Kidney, and CHANCE-Bladder, for the early detection of breast, liver, kidney, and bladder cancers. In addition, the study will assess a human-AI collaborative framework to determine its potential for improving cancer detection and reducing missed diagnoses in clinical practice.",[29],"NOT_YET_RECRUITING","2026-06-05",{"date":63,"type":39},"2026-06-10",{"date":65,"type":21},"2026-07",{"date":67,"type":21},"2028-07",{"name":69,"class":46},"Lian Yang",{"id":71,"slug":72,"hasResults":12,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":82,"conditions":83,"keywords":87,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":47},"100628757","a-first-in-human-study-of-the-cipher-system-during-brain-surgery-for-newly-diagnosed-glioma-100628757","NCT07465796","A First-in-Human Study of the CIPHER System During Brain Surgery for Newly Diagnosed Glioma","CIPHER","Inclusion Criteria:\n\n* Newly diagnosed supratentorial glioma requiring resection\n* Glioma mass reaches or close to cortical surface\n* Adults aged 18-75\n* Planned for open craniotomy under Total Intravenous Anesthesia (TIVA)\n* Patient able to provide informed consent\n* Performance status: Eastern Cooperative Oncology Group (ECOG) scale 0-2\n\nExclusion Criteria:\n\n* Prior craniotomy at the same anatomical location\n* Plan for awake craniotomy\n* Any history of seizures prior to craniotomy\n* Any history of coagulopathy or coagulation disorders\n* Pregnant status during craniotomy","75 Years",{"count":79,"type":21},10,[81],"NA","The goal of this clinical trial is to collect data on the use of the CIPHER System when used by a surgeon during brain tumor removal. The main questions it aims to answer are:\n\n* To evaluate the safety of the CIPHER System when used during brain tumor surgery (Primary)\n* To evaluate the function of the electrodes under recording and stimulating conditions during surgery (Secondary) Participants will undergo standard-of-care surgery to remove their tumor. Just before the tumor is removed, the CIPHER System will be tested on the main tumor and the surrounding margin areas. Participants will be monitored during standard hospital visits occurring during the recovery period after surgery as well as two- and six-weeks after surgery.",[84,29,85,86],"Glioma","Electrocorticography","Brain",[88,89,90,91],"Intraoperative Neurophysiology","Cortical Mapping","Cortical Stimulation","Brain-Computer Interface (BCI)","2026-06-01",{"date":94,"type":39},"2026-06-03",{"date":96,"type":39},"2026-05-22",{"date":98,"type":21},"2026-09",{"name":100,"class":101},"Coherence Neuro Australia Pty Limited","INDUSTRY",{"id":103,"slug":104,"hasResults":12,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":47},"100593009","a-study-of-live-tumor-fragments-of-surgical-resections-100593009","NCT07000864","A Study of Live Tumor Fragments of Surgical Resections","Predicting Response to Therapy From Analysis of Live Tumor Fragments of Surgical Resections","Inclusion Criteria:\n\n* Ability to understand and sign informed consent\n* Planning to undergo a surgical procedure to remove cancer\n\nExclusion Criteria:\n\n* Does not meet Inclusion criteria\n* No tissue for research available at time of surgery",{"count":110,"type":21},250,"The purpose of this study is to obtain unused resected tumor tissue sample and associated clinical data from patients enrolled in this study to research ex vivo treatment response and integrity of tumor microenvironment using omics analysis and imaging while maintaining cell stability in a live environment.",[113,29],"Cancer","2026-05-19",{"date":96,"type":39},{"date":117,"type":39},"2025-07-01",{"date":119,"type":21},"2028-06-01",{"name":121,"class":46},"Mayo Clinic",{"id":123,"slug":124,"hasResults":12,"nctId":125,"briefTitle":126,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":128,"enrollmentInfo":129,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":131,"conditions":132,"keywords":134,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":47},"100574058","68ga-nk224-pet-imaging-of-pd-l1-expression-in-cancers-100574058","NCT06754345","68Ga-NK224 PET Imaging of PD-L1 Expression in Cancers","Inclusion Criteria:\n\n* (i) adult patients (aged 18 years or order);\n* (ii) patients with newly diagnosed or previously treated malignant tumors (supporting evidence may include magnetic resonance imaging (MRI), CT, tumor markers and pathology report);\n* (iii) patients who had scheduled 68Ga-NK224 PET\u002FCT scans;\n* (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n* (i) patients with non-malignant lesions;\n* (ii) patients with pregnancy;\n* (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.","90 Years",{"count":130,"type":21},100,"To evaluate the potential usefulness of 68Ga-NK224 positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the evaluation of PD-L1 expression in primary and\u002For metastatic tumors, compared with histopathological results.",[29,133],"PD-L1",[29,133,135,136],"PET\u002FCT","diagnosis","2026-05-13",{"date":139,"type":39},"2026-05-15",{"date":141,"type":39},"2023-05-30",{"date":143,"type":21},"2026-11-30",{"name":145,"class":46},"The First Affiliated Hospital of Xiamen University",{"id":147,"slug":148,"hasResults":12,"nctId":149,"briefTitle":150,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":22,"phases":154,"briefSummary":155,"conditions":156,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":157,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":47},"100506804","phase-2-evaluation-of-the-response-and-non-response-of-nirogacestat-in-desmoid-tumors--clinical-study-100506804","NCT05879146","Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study","Inclusion Criteria:\n\nThis study will enroll approximately 40 participants diagnosed with DT. Participants must meet the following eligibility criteria to be enrolled:\n\n1. Age ≥ 18 years. Individuals younger than 18 years old are excluded. More than 99% of the population evaluated at MDACC with a diagnosis of DT is older than 18. Sixty-three percent of the population with a diagnosis of DT evaluated at MDACC are 10 - 54 years old. The remaining 37 percent are older than 54 years old. Additionally, most of the robust data related to dosing or adverse event data currently available on the use of nirogacestat is in adults\n2. Histologically documented DT with evidence of radiographic tumor progression (≥ 10% or absolute increase in dimensions of ≥ 10 mm in maximal diameter) in unidimensional measurement within the previous 18 months. Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension as ≥10 mm (≥1 cm) with CT scan, MRI, or calipers by clinical exam\n\n   1. Recurrent or primary disease\n   2. Symptomatic disease or impending morbidity (as defined by physician) and patient and physician agree treatment would be of benefit\n3. Treatment naïve or progression on or after any prior therapy for DT. Participant must have discontinued prior therapy for at least 28 days or 5 half-lives of the drug, whichever is greater. All toxicities from prior therapy must be resolved to Grade ≤ 1 or clinical baseline. There is no limit on the number of previous systemic treatments received\n4. Able to tolerate radiographic progression (up to 20% increase in tumor longest diameter) as determined by treating oncologist based on morbidity and tumor growth is not threatening vital structures\n5. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2\n6. Are appropriate for systemic therapy\n7. Have accessible tumors for serial biopsies\n8. Agree to provide new tumor tissue. Tumor tissue from the archival (tumor bank) may be used if the biopsy is performed after discontinuation of prior therapy and the participant must have discontinued prior therapy for at least 28 days or five half-lives of the drug, whichever is greater\n9. For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated\n10. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load\n11. Adequate organ and bone marrow function as defined by the following screening laboratory values:\n\n    1. Absolute neutrophil count ≥ 1500 cells\u002FμL;\n    2. Platelets ≥ 100,000 μL;\n    3. Hemoglobin ≥ 9 g\u002FdL;\n    4. Total bilirubin ≤ 1.5 × upper limit of normal (ULN) (isolated bilirubin \\> 1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin \\\u003C 35%);\n    5. Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase)\u002Falanine aminotransferase (ALT) (serum glutamic pyruvate transaminase) ≤ 2 × ULN; and\n    6. If Creatinine \\> 1.5 x ULN then calculated creatinine clearance must be . 60 mL\u002Fmin (using the Cockcroft-Gault formula).\n12. Can swallow tablets and have no gastrointestinal conditions affecting absorption\n13. Agree to the use of adequate contraception during the treatment period and for at least 4 months for men and women after the last dose of the study treatment (see Appendix 1 for more information)\n14. Have the ability to understand and the willingness to sign a written informed consent document\n15. English and non-English speaking patients\n16. Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this study\n17. Participants with a known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification; to be eligible for this study, participants should be class 2B or better\n\nExclusion Criteria:\n\nParticipants are excluded from this study if any of the following criteria apply:\n\n1. Unable to undergo serial biopsies\n2. Participants with familial adenomatous polyposis\n3. Unable to tolerate MRI or for whom MRI is contraindicated\n4. Pregnant or breastfeeding women are excluded from this study. Based on findings in animal studies, oral administration of nirogacestat to pregnant rats during the period of organogenesis resulted in embryo-fetal toxicities at maternal exposures that were significantly lower than adult human exposures at the recommended dose of 150 mg twice daily. Nirogacestat should be avoided during pregnancy\n\n   There is no data regarding the presence of nirogacestat or its metabolites in either human or animal milk or its effects on a breastfed child or on milk production. Because of the potential for serious adverse reactions in a breastfed child from nirogacestat, advise women not to breastfeed during treatment with nirogacestat.\n5. Known hypersensitivity to nirogacestat or any of its excipients\n6. Participants requiring the use of any excluded concomitant medications listed in Table 2 during the course of the study\n7. Unable to comply with study-related procedures in the opinion of the investigator\n8. Patients with cognitive impairment requiring a legally authorized representative for consent\n9. Patients with uncontrolled intercurrent illness (Indicate clearly what type or extent)\n10. Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with positive viral load will be excluded\n11. Patients with psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n12. Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \\> Grade 1) with the exception of alopecia\n13. Patients who are receiving any other investigational agents\n14. Patients with an additional malignancy and brain metastases. There is not enough evidence of the effects of nirogacestat in other malignancies at this time\n15. Participant has experienced any of the following within 6 months of signing informed consent:\n\n15.1 clinically significant cardiac disease (New York Heart Association Class III or IV); 15.2 myocardial infarction; 15.3 severe\u002Funstable angina; 15.4 coronary\u002Fperipheral artery bypass graft; 15.5 symptomatic congestive heart failure; 15.6 cerebrovascular accident; 15.7 transient ischemic attack; or 15.8 symptomatic pulmonary embolism.",{"count":153,"type":21},40,[24],"To learn about the safety and effects of an investigational drug called nirogacestat when given to participants with a desmoid tumor\u002Faggressive fibromatosis",[29],{"date":139,"type":39},{"date":159,"type":39},"2024-11-26",{"date":161,"type":21},"2028-01-31",{"name":163,"class":46},"M.D. Anderson Cancer Center",{"id":165,"slug":166,"hasResults":12,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":22,"phases":172,"briefSummary":173,"conditions":174,"keywords":176,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":47},"100548145","phase-2-bladder-preservation-for-patients-with-muscle-invasive-bladder-cancer-mibc-with-variant-histology-100548145","NCT06417190","Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology","IIT2023-13-BALLAS-VHTMT: Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology","Inclusion Criteria:\n\n* Documented diagnosis of MIBC with variant histology, cT2-T4N0M0, confirmed by TURBT and CT C\u002FA\u002FP and\u002For PET.\n* Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.\n\nExclusion Criteria:\n\n* Evidence of diffuse cis on pathology\n* Presence of bilateral hydronephrosis (if hydronephrosis is present, can only be unilateral)\n* Prior radiotherapy to the pelvis\n* History of systemic therapy for MIBS\n* Presence of concurrent cancer (remote history of cancer (\\>5 years) allowed if the patient is without evidence of disease)",{"count":20,"type":21},[24],"This is a Phase II, single cohort study designed to evaluate outcomes in patients with muscle invasive bladder cancer (MIBC) with variant histology who receive neoadjuvant chemotherapy (NAC) with or without immunotherapy (IO) followed by trimodal therapy (TMT). Enrolled patients will undergo at least 3 cycles of NAC +\u002F- IO (oncologist's choice) followed by a four- or six-week course of concurrent standard of care chemotherapy and radiation therapy. These patients will be compared with historical controls of patients with a diagnosis of pure urothelial carcinoma who have undergone TMT. This study has been designed to test the hypothesis that variant histology TMT can be delivered within 45 days of NAC +\u002F- IO and is therefore a viable option in patients who are risk of systemic disease spread.",[175,29],"Muscle-Invasive Bladder Carcinoma",[177,178,179],"Trimodal Therapy (TMT)","Neoadjuvant Chemotherapy","muscle-invasive urothelial cell bladder cancer (MIBC)","2026-05-01",{"date":182,"type":39},"2026-05-04",{"date":184,"type":39},"2026-01-16",{"date":186,"type":21},"2030-12",{"name":188,"class":46},"Leslie Ballas",{"id":190,"slug":191,"hasResults":12,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":22,"phases":197,"briefSummary":198,"conditions":199,"keywords":201,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":47},"100623670","artificial-intelligence-guided-detection-of-blood-vessels-to-enhance-safety-in-third-space-endoscopic-procedures-100623670","NCT07399652","Artificial Intelligence-Guided Detection of Blood Vessels to Enhance Safety in Third-Space Endoscopic Procedures","Artificial Intelligence-Guided Detection of Anatomical Markers to Enhance Safety in Third-Space Endoscopic Procedures","Inclusion Criteria:\n\n* Patients diagnosed with Achalasia Cardia or neoplasms.\n\nExclusion Criteria:\n\n* Patients with conditions deemed unsuitable for third space endoscopy procedures (e.g.: Candidiasis)",{"count":20,"type":21},[81],"This prospective study aims to evaluate the performance of a novel Artificial Intelligence (AI) clinical decision support tool during third space endoscopic procedures, such as Endoscopic Submucosal Dissection (ESD) and Peroral Endoscopic Myotomy (POEM).\n\nWhile these procedures are effective for treating gastrointestinal neoplasms and motility disorders, they carry risks of intraprocedural bleeding and perforation if submucosal blood vessels are not correctly identified and coagulated. Building on previous retrospective validation, this study will assess whether a real-time artificial intelligence model can assist endoscopists in detecting and delineating blood vessels more accurately and faster during live human procedures.",[200,29],"Achalasia Cardia",[202,203,204,205,206,207],"Artificial Intelligence","Third Space Endoscopy","POEM","ESD","STER","EMR","2026-04-14",{"date":210,"type":39},"2026-04-15",{"date":212,"type":39},"2026-02-10",{"date":214,"type":21},"2026-04-30",{"name":216,"class":46},"Asian Institute of Gastroenterology, India",{"id":218,"slug":219,"hasResults":12,"nctId":220,"briefTitle":221,"officialTitle":221,"acronym":4,"eligibilityCriteria":222,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":22,"phases":225,"briefSummary":226,"conditions":227,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":47},"100444196","phase-2-phase-ii-study-of-pembrolizumab-in-combination-with-lenvatinib-in-patients-with-tnbc-nsclc-and-other-tumor-types-and-brain-metastases-100444196","NCT05064280","Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases","Inclusion Criteria:\n\nPatients are eligible to be included in the study only if all the following criteria apply:\n\n1. Male\u002Ffemale patients who are at least 18 years of age on the day of signing informed consent with histologically or cytologically confirmed TNBC (Cohort 1), NSCLC (Cohort 2), or solid tumors other than TNBC and NSCLC (Cohort 3) with brain metastasis and with or without active extracranial disease will be enrolled in this study.\n2. Has at least 1 measurable brain metastasis: Presence of at least 1 independently verified measurable brain metastasis in accordance with mRECIST (Appendix 1) that can be accurately assessed at baseline and suitable for accurate repeated measurements and with a tumor diameter of 0.5-3 cm on magnetic resonance imaging \\[MRI\\]).\n\n   * Previous SRS and excision of up to 5 brain metastases are permitted at least 3 weeks prior to study treatment initiation, provided that neurologic sequelae have completely resolved and measurable untreated lesion(s) remain. If the patient had prior whole brain radiation therapy or SRS, progression in any measurable brain metastasis must have occurred at least 1 month after the end of radiation therapy for the irradiated lesion to be counted as measurable.\n   * Patients can have asymptomatic (no neurologic signs or symptoms, not requiring immediate local intervention \\[surgery or radiosurgery\\] or systemic glucocorticoid therapy \\[within 10 days prior to study treatment initiation\\]) OR minimally symptomatic brain metastases (requiring ≤10 mg prednisone or equivalent per day and not requiring immediate surgical or radiation therapy in the opinion of the treating investigator and a radiation therapy or neurosurgical consultant).\n3. Extracranial disease is not required and if present, it can be measurable or non-measurable (RECIST v1.1).\n4. A female patient is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:\n\n   1. Not a woman of childbearing potential (WOCBP) as defined in Appendix 6 OR\n   2. A WOCBP who agrees to follow the contraceptive guidance in Appendix 6 during the treatment period and for at least 120 days after the last dose of study treatment.\n5. A male patient must agree to use contraception as detailed in Appendix 6 of this protocol during the treatment period and for at least 120 days after the last dose of study treatment and refrain from donating sperm during this period.\n6. The patient (or legally acceptable representative if applicable) provides written informed consent for the study.\n7. Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (Appendix 7).\n8. Has a life expectancy ≥12 weeks.\n9. Has adequate organ function within 28 days of study treatment initiation as defined below:\n\n   * Absolute neutrophil count ≥1000\u002FµL (without granulocyte colony-stimulating factor support within 2 weeks of laboratory test used to determine eligibility)\n   * Platelet count ≥100 000\u002FµL (without transfusion within 2 weeks of laboratory test used to determine eligibility)\n   * Hemoglobin ≥9.0 g\u002FdL\n   * Total bilirubin ≤1.5 × upper limit of normal (ULN); if hepatic metastases are present, ≤2.0 × ULN\n   * Aspartate transaminase (AST) and alanine transaminase (ALT) ≤2.5 × ULN; if hepatic metastases are present, ≤5.0 × ULN\n   * Creatinine clearance ≥50 mL\u002Fmin\n   * International normalized ratio (INR) OR prothrombin time (PT) and activated partial thromboplastin time (aPTT) ≤1.5 × ULN.\n10. Adequately controlled blood pressure with 0 or 1 antihypertensive medication (defined as blood pressure ≤150\u002F90 mmHg at screening and no changes in antihypertensive medication within 7 days of Day 1 of Cycle 1).\n11. Hepatitis B and C screening tests are not required unless:\n\n    * Known history of HBV or HCV infection\n    * As mandated by local health authority 11.1 Hepatitis B positive subjects\n    * Participants who are HBsAg positive are eligible if they have received HBV antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to randomization.\n    * Participants should remain on anti-viral therapy throughout study intervention and follow local guidelines for HBV anti-viral therapy post completion of study intervention\n\n11.2 Participants with history of HCV infection are eligible if HCV viral load is undetectable at screening.\n\n• Participants must have completed curative anti-viral therapy at least 4 weeks prior to randomization.\n\nExclusion Criteria:\n\nPatients are excluded from the study if any of the following criteria apply, unless medically indicated and after approval by study chair\u002FIRB office:\n\n1. Has NSCLC with an oncogenic driver mutation (mutation\\[s\\] in EGFR, ERBB2, or BRAF V600E; fusion\u002Frearrangement\\[s\\] in ALK, ROS1, NTRK, or RET; or MET amplification). KRAS or PIK3CA mutation are allowed.\n2. Has hepatocellular carcinoma. NOTE: patients with hepatocellular carcinoma and brain metastasis are excluded from this trial because the dose of lenvatinib approved for this disease is different than the ones used in this trial.\n3. Has symptomatic or untreated spinal cord compression. Patients with clinical or radiographic evidence of leptomeningeal metastases or other metastatic systemic disease are not allowed. In cases where brain metastases are superficially located (cortical-based brain metastasis) and leptomeningeal spread is suspected, a work-up for leptomeningeal disease (LMD) should be performed (MRI and lumbar puncture with CSF cytology). If LMD is not confirmed, the treating physician, neuro-oncologist, or brain metastasis multidisciplinary team should make a clinical call and exclude the patient if LMD dissemination is likely.\n4. Has received prior therapy with lenvatinib or other antiangiogenic tyrosine kinase inhibitor alone or in combination with a PD-1\u002FPD-L1 inhibitor. Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD L2, or anti-CTLA-4 agent or chemotherapy is allowed.\n5. Has received prior systemic anticancer therapy including investigational agents within 28 days prior to study treatment initiation.\n\n   * Patients must have recovered from all AEs due to previous therapies to ≤ Grade 1 or baseline. Patients with ≤ Grade 2 neuropathy may be eligible. Patients with immunotherapy-related AEs of a permanent nature but manageable (hypothyroidism on thyroid hormone replacement, vitiligo, etc.) are eligible.\n   * Patients must have recovered adequately from any complications from major surgery. Withhold lenvatinib treatment for at least 1 week prior to elective surgery. Do not administer lenvatinib for at least 2 weeks following major surgery and until adequate wound healing.\n6. Has received radiotherapy within 14 days prior to study treatment initiation. Patients must have recovered from all radiation-related toxicities, not require corticosteroids in dosing exceeding 10 mg daily of prednisone equivalent, and not have had radiation pneumonitis. Any radiation to the brain or spinal cord\u002Fcauda equina must have been completed within \\>3 weeks from study treatment initiation.\n7. Has received a live vaccine or live-attenuated vaccine within 30 days prior to study treatment initiation. Administration of killed vaccines is allowed.\n8. Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 28 days or 5 half-lives, whichever is shorter, prior to study treatment initiation.\n\n   Note: Patients who have entered the follow-up phase of an investigational study may participate as long as it has been 28 days after the last dose of the previous investigational agent.\n9. Contraindications to MRI (implanted metal device or foreign bodies) or MRI contrast (insufficient renal function or allergy).\n10. A WOCBP who has a positive screening serum pregnancy test within 7 days prior to Day 1 of Cycle 1 (see Appendix 6).\n11. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to study treatment initiation.\n12. Has a known additional malignancy that is progressing or has required active treatment within the past 5 years.\n\n    Note: Patients with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.\n13. Has severe hypersensitivity (≥ Grade 3) to pembrolizumab or lenvatinib and\u002For any of their excipients.\n14. Has a condition requiring systemic treatment with either corticosteroids (\\>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of study treatment initiation. Inhaled or topical steroids, and adrenal replacement steroid doses ≤10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.\n15. Has a history of (non-infectious) pneumonitis\u002Finterstitial lung disease that required steroids or has current pneumonitis\u002Finterstitial lung disease.\n16. Has an active infection requiring systemic therapy.\n17. Has a known history of human immunodeficiency virus.\n18. Concurrent active Hepatitis B (defined as HBsAg positive and\u002For detectable HBV DNA) and Hepatitis C virus (defined as anti-HCV Ab positive and detectable HCV RNA) infection.\n\n    Note: Hepatitis B and C screening tests are not required unless:\n    * Known history of HBV and HCV infection\n    * As mandated by local health authority\n19. Active tuberculosis (Bacillus Tuberculosis).\n20. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the treating investigator.\n21. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.\n22. Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study treatment.\n23. GI tract disease causing the inability to take oral medication, malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures affecting absorption, or uncontrolled inflammatory GI disease (e.g., Crohn's disease, ulcerative colitis).\n24. Unable to swallow and retain oral medications.\n25. Has significant cardiac impairment including but not limited to history of congestive heart failure greater than New York Heart Association Class II (Appendix 8), unstable angina, myocardial infarction or stroke within previous 6 months, or cardiac arrhythmia requiring medical treatment at the time of screening.\n26. Has prolongation of QTc using Fridericia's formula (QTcF) to \\>480 ms.\n27. Has gastric or esophageal varices that may require treatment.\n28. Having a GI bleeding event or active hemoptysis (bright red blood of at least 0.5 teaspoon) with 28 days of enrollment.\n29. Has bleeding or thrombotic disorder(s) or uses anticoagulants such as warfarin or similar agents requiring therapeutic INR monitoring. Treatment with low molecular weight heparin is allowed.\n30. Electrolyte abnormalities that have not been corrected.\n31. Patients having \\>1+ proteinuria on urine dipstick testing unless a 24-hour urine collection for quantitative assessment indicates that the urine protein is \\\u003C1 g\u002F24 hours.\n32. Has had an allogeneic tissue\u002Fsolid organ transplant.\n33. Has radiographic evidence of intratumoral cavitation, encasement, or invasion of a major blood vessel.",{"count":224,"type":21},104,[24],"This is a single-center, open-label, multi-cohort Phase II study evaluating the efficacy and safety of pembrolizumab in combination with lenvatinib in patients with solid tumors and brain metastases.\n\nThe study will be comprised of 3 patient cohorts: triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), and solid tumor types other than TNBC and NSCLC. Cohort 3 will be comprised of solid tumor types with established (e.g., renal cell carcinoma \\[RCC\\], endometrial cancer) or preliminary clinical evidence (e.g., gastric cancer, colorectal cancer) of efficacy of programmed cell death-1 (PD-1) and angiogenesis inhibitors. The study will be conducted using a Simon's optimal two-stage design, and approximately 87 patients will be enrolled concurrently (n=29 per cohort).\n\nThe primary endpoint is intracranial objective response rate (ORR) as assessed by the modified Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.",[228,29],"Brain Metastases","2026-04-13",{"date":231,"type":39},"2026-04-16",{"date":233,"type":39},"2022-01-20",{"date":235,"type":21},"2028-02-28",{"name":163,"class":46},{"id":238,"slug":239,"hasResults":12,"nctId":240,"briefTitle":241,"officialTitle":241,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":243,"enrollmentInfo":244,"targetDuration":4,"studyType":22,"phases":246,"briefSummary":248,"conditions":249,"keywords":251,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":47},"100604020","phase-1-application-of-ga-fxx489-nns309-petct-imaging-in-diagnosis-of-tumor-diseases-100604020","NCT07144085","Application of ⁶⁸Ga-FXX489 (NNS309) PET\u002FCT Imaging in Diagnosis of Tumor Diseases.","Inclusion Criteria:\n\n1. Patients with a high suspicion of oncological diseases.\n2. Age: 18-80 years, no gender restriction, able to express themselves independently, and willing to participate in this study with a signed informed consent form.\n\nExclusion Criteria:\n\n1. Failure to sign the informed consent form.\n2. Severe visual or auditory impairment, cognitive disorders, or patients with claustrophobia who cannot communicate effectively.\n3. Severe cardiac dysfunction, cardiac function class III-IV.\n4. Renal failure (serum creatinine level \\> 1.2 mg\u002Fdl).\n5. Allergy to alcohol.\n6. Use of drugs within 1 week prior to the examination that can cause a disulfiram-like reaction with alcohol, such as penicillins, cephalosporins, or cefotetan.\n7. Known pregnancy.","80 Years",{"count":245,"type":21},30,[247],"PHASE1","A new radiotracer, 68Ga-FXX489 (NNS309), has been developed for tracking fibroblast activation protein (FAP) and visualizing the tumor stroma. The purpose of the study is to explore the diagnostic value of 68Ga-FXX489 (NNS309) PET\u002FCT imaging in oncological diseases, to assess its safety, imaging characteristics, and biodistribution after administration.",[29,250],"Metastatic Cancer",[252,253],"FAP","CAF","2026-03-30",{"date":256,"type":39},"2026-04-03",{"date":258,"type":39},"2025-09-11",{"date":260,"type":21},"2027-07-30",{"name":262,"class":46},"Yi Tian",{"id":264,"slug":265,"hasResults":12,"nctId":266,"briefTitle":267,"officialTitle":267,"acronym":4,"eligibilityCriteria":268,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":269,"enrollmentInfo":270,"targetDuration":4,"studyType":22,"phases":271,"briefSummary":272,"conditions":273,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":47},"100628629","phase-1-application-of-68gaga-ni-fapi-04-petct-imaging-in-fibroblast-activation-protein-related-diseases-100628629","NCT07464132","Application of [68Ga]Ga-NI-FAPI-04 PET\u002FCT Imaging in Fibroblast Activation Protein Related Diseases","Inclusion Criteria:\n\n* 1: 18-85 years old\n\n  2: Tumor patients can undergo surgery or biopsy to obtain pathological diagnosis\n\n  3: Ability to understand and sign informed consent forms\n\n  4: Expected survival period exceeding 6 months and able to receive follow-up\n\n  5: Healthy volunteers without chronic medical history of hypertension, diabetes, coronary heart disease, kidney disease, tumor, etc\n\nExclusion Criteria:\n\n* 1: Pregnant or lactating women\n\n  2: Patients allergic to research drug ingredients\n\n  3: Patients with severe liver and kidney dysfunction (blood creatinine levels exceeding 159 μ mol\u002FL)\n\n  4: Patients who participate in other clinical trials and interfere with the results of this study\n\n  5: Patients with severe illness who cannot cooperate with the examination","85 Years",{"count":245,"type":21},[247,24],"The purpose of this study is to conduct clinical research on \\[68Ga\\] Ga-NI-FAPI-04 PET\u002FCT imaging and further investigate its diagnostic value in fibroblast activation related diseases.",[29,274,275,276,277,278],"Cardiovascular Diseases","Pulmonary Fibrosis","Rheumatic Immune Diseases Involving Large Blood Vessels","Hypertrophic Cardiomyopathy (HCM)","Other Hypoxic and Fibroblast Activated Diseases","2026-03-09",{"date":281,"type":39},"2026-03-11",{"date":283,"type":39},"2025-12-17",{"date":285,"type":21},"2027-06-17",{"name":287,"class":46},"Peking Union Medical College Hospital",{"id":289,"slug":290,"hasResults":12,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":294,"eligibilityCriteria":295,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":296,"targetDuration":298,"studyType":57,"phases":4,"briefSummary":299,"conditions":300,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":345,"locationsCount":347},"100368284","the-momentum-study-the-multiple-outcome-evaluation-of-radiation-therapy-using-the-mr-linac-study-100368284","NCT04075305","The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study","The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study","MOMENTUM","Inclusion Criteria:\n\n* Patient is to undergo or has completed imaging or treatment procedures on an MR-Linac;\n* Patient provides written, informed consent;\n* Patient is 18 years old or older.\n\nExclusion Criteria:\n\n* MRI exclusion criteria, including\n* MRI contraindications as per usual clinical care, such as (possible) pregnancy; claustrophobia and metal or electronic implants not compatible with MRI.",{"count":297,"type":21},8000,"2 Years","The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further technical development of the MR-Linac system with the ultimate purpose to improve patients' survival, local, and regional tumor control and quality of life.",[301,302,303,304,305,306,307,308,309,310,311,312,313,314,315,316,317,318,319,320,321,322,323,324,325,326,327,328,329,330,29,331,332,333,334,335,336,337],"Oncology","Breast Cancer","Prostate Cancer","Gynecologic Cancer","Brain Tumor","Brain Cancer","Gynecologic Tumor","Prostate Tumor","Prostate Neoplasm","Breast Tumor","Radiation Toxicity","Quality of Life","Rectal Cancer","Rectal Tumor","Rectal Neoplasms","Lung Cancer","Lung Tumor","Lung Neoplasm","Esophageal Cancer","Esophagus Cancer","Esophageal Tumor","Esophageal Neoplasm","Esophagus Tumor","Esophagus Neoplasm","Pancreatic Cancer","Pancreatic Tumor","Pancreatic Neoplasms","Head and Neck Cancer","Head and Neck Neoplasms","Head and Neck Tumor","Neoplasms","Bladder Cancer","Bladder Neoplasm","Liver Cancer","Liver Neoplasms","Liver Metastases","Oligometastases","2026-03-03",{"date":340,"type":39},"2026-03-05",{"date":342,"type":39},"2019-02-01",{"date":344,"type":21},"2030-08-01",{"name":346,"class":46},"UMC Utrecht",18,{"id":349,"slug":350,"hasResults":12,"nctId":351,"briefTitle":352,"officialTitle":352,"acronym":353,"eligibilityCriteria":354,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":355,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":357,"conditions":358,"keywords":363,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":47},"100527786","development-of-new-diagnostic-tools-in-capsule-endoscopy-100527786","NCT06152289","Development of New Diagnostic Tools in Capsule Endoscopy","NOCE","Inclusion Criteria:\n\n\\- Any patient in whom a capsule endoscopy examination is performed as part of routine care.\n\nExclusion Criteria:\n\n\\- Opposition to the use of images and videos from daily, routine care for research purposes.",{"count":356,"type":21},10000,"Patients participating to this study will provide images and videos of capsule endoscopy to train, tune and evaluate technological bricks of artificial intelligence solutions, in order to improve diagnostic performances of the procedure, while reducing reading time by physicians.",[359,360,361,362,29],"Bowel Disease","Crohn Disease","Celiac Disease","Chronic Diarrhea",[364,365,366],"Small bowel","Capsule endoscopy","Artificial intelligence","2026-02-27",{"date":369,"type":39},"2026-03-02",{"date":371,"type":39},"2023-02-10",{"date":373,"type":21},"2028-02",{"name":375,"class":46},"Assistance Publique - Hôpitaux de Paris",{"id":377,"slug":378,"hasResults":12,"nctId":379,"briefTitle":380,"officialTitle":380,"acronym":4,"eligibilityCriteria":381,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":382,"targetDuration":4,"studyType":22,"phases":383,"briefSummary":384,"conditions":385,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":388,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":47},"100627131","predictt-clinical-trial-prospective-evaluation-of-pressure-enabled-delivery-and-alterations-in-ct-based-tumor-to-normal-liver-ratio-and-tumor-dose-using-the-trinav-infusion-system-100627131","NCT07444645","PREDICTT Clinical Trial: Prospective Evaluation Of Pressure-Enabled Delivery And Alterations In CT-Based Tumor-To-Normal Liver Ratio And Tumor Dose Using The Trinav Infusion System","Inclusion Criteria:\n\n1. Patients over 18 years of age, of any race or sex, who have unresectable primary or metastatic tumors of the liver, and who are able to give informed consent\n2. Patients must be eligible for Y90-radioembolization treatment, have an ECOG Performance Status score of ≤ 2, with a life expectancy of ≥ 3 months\n3. At least one lesion ≥ 3.0 cm in shortest dimension\n4. Negative pregnancy test in premenopausal women with an acceptable contraception\n5. Plan to perform bilobar, lobar or sectoral treatment using partition dosimetry\n6. Evidence of partial or complete tumor vascularity based on pre-procedure liver protocol CT scan or MRI with contrast or intraprocedural hybrid angio CT as well as subjectively similar tumor vascularity between right and left lobes if bilobar treatment is planned\n7. Right or left hepatic artery diameter of 1.5 mm to 5 mm (the recommended vessel size range for the TriNav Infusion System) based on pre-procedure arterial phase CT or intraprocedural hybrid angio CT\n\nExclusion Criteria:\n\n1. Contraindications to angiography and selective visceral catheterization\n2. Evidence of potential delivery of greater than 30 Gy absorbed dose to the lungs with a single treatment session\n3. CT based TNR of 3 or higher based on planning hybrid angioCT\n4. Evidence of any detectable Tc-99m MAA flow to the stomach or duodenum, after application of established angiographic techniques to stop or mitigate such flow (eg, placing catheter distal to gastric vessels)\n5. Infiltrative tumors",{"count":20,"type":21},[81],"This single-arm prospective study will compare CT-based tumor-to-normal ratio (TNR) measurements obtained using TriNav versus endhole microcatheters.",[29,386],"Liver","2026-02-26",{"date":338,"type":39},{"date":390,"type":21},"2026-08-01",{"date":392,"type":21},"2030-07-31",{"name":163,"class":46},{"id":395,"slug":396,"hasResults":12,"nctId":397,"briefTitle":398,"officialTitle":399,"acronym":4,"eligibilityCriteria":400,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":401,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":403,"conditions":404,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":407,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":413,"locationsCount":47},"100622371","decoupling-immunotherapy-toxicity-and-cancer-response-100622371","NCT07382752","Decoupling Immunotherapy Toxicity and Cancer Response","Metabolomic and Genetic Factors Decoupling Immune Checkpoint Inhibitor Tumor Efficacy and Cardiovascular Toxicity","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Plan to start immune checkpoint inhibitor for cancer therapy\n\nExclusion Criteria:\n\n1. No baseline blood collection prior to initiation\n2. At time of evaluation not determined to be a good candidate for evaluation of outcome events by the principal investigator",{"count":402,"type":21},1200,"This study is a novel evaluation of cardiotoxicity after ICI therapy based on traditional CV risk factors with the addition of metabolomic profiles, epigenetic aging, and CHIP. It is not an extension of previous work in ICI therapy.",[29,405],"Cardiovascular","2026-01-26",{"date":408,"type":39},"2026-02-03",{"date":410,"type":39},"2026-01-09",{"date":412,"type":21},"2030-06-30",{"name":163,"class":46},{"id":415,"slug":416,"hasResults":12,"nctId":417,"briefTitle":418,"officialTitle":419,"acronym":4,"eligibilityCriteria":420,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":421,"targetDuration":4,"studyType":22,"phases":423,"briefSummary":424,"conditions":425,"keywords":430,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":445,"locationsCount":447},"100515861","phase-2-trial-of-nab-sirolimus-in-combination-with-letrozole-in-patients-with-advanced-or-recurrent-endometrioid-endometrial-cancer-100515861","NCT05997017","Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer","A Phase 2 Multi-center Open-label Trial of Nab-Sirolimus in Combination With Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer","Inclusion Criteria:\n\n1. Patients must have clinically confirmed advanced or recurrent endometrioid endometrial carcinoma. Histologic documentation of the recurrence is suggested but not required.\n2. All patients must have 1 or more measurable target lesion at baseline by computed tomography (CT; or magnetic resonance imaging \\[MRI\\] if CT scans are contraindicated) as defined by RECIST version 1.1.\n3. Patients must have EEC that is metastatic or locally advanced where surgical resection is not an option or likely to result in severe morbidity.\n4. Prior treatment history:\n\n   1. Adjuvant setting - treatment with chemotherapy, hormonal therapy,checkpoint inhibitors, and\u002For other therapy is permitted as long as theadjuvant therapy ended ≥6 months from enrollment.\n   2. Recurrent\u002Fadvanced\u002Fmetastatic setting - treatment with 0-1 prior chemotherapy regimens is permitted (patients may be naïve to chemotherapy); chemotherapy must have been completed ≥3 months prior to enrollment. Patients are permitted to have received adjuvant chemotherapy and no more than 1 line of chemotherapy in the recurrent\u002Fadvanced\u002Fmetastatic setting.\n   3. Non-chemotherapy-based treatment (eg, checkpoint inhibitors, hormonal therapy, and\u002For small molecule agents) is permitted at any point as long as therapy ended ≥4 weeks prior to enrollment.\n   4. Patients who have received prior therapy in the recurrent\u002Fadvanced\u002Fmetastatic setting must have achieved a complete or partial response(investigator-assessed) to at least 1 therapy.\n5. Age: 18 years or older.\n6. Patient must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n7. Adequate liver function:\n\n   1. Total bilirubin ≤1.5 × upper limit of normal (ULN) (unless due to Gilbert's syndrome, then ≤3 × ULN)\n   2. Aspartate aminotransferase (AST) ≤2.5 × ULN (≤5 × ULN if attributable to liver metastases)\n8. Adequate renal function: creatinine clearance (CrCL) ≥30 mL\u002Fmin based on Cockcroft-Gault\n9. Adequate hematologic parameters:\n\n   1. Absolute neutrophil count (ANC) ≥1.0 × 109\u002FL (growth factor support allowed)\n   2. Platelet count ≥100,000\u002Fmm3 (100 × 109\u002FL) (transfusion and\u002For growth factor support allowed)\n   3. Hemoglobin ≥8.0 g\u002FdL (transfusion and\u002For growth factor support allowed)\n10. Fasting serum triglyceride must be ≤300 mg\u002FdL; fasting serum cholesterol must be less than or equal to 350 mg\u002FdL.\n11. Minimum of 4 weeks since any major surgery, completion of radiation, or completion of prior systemic anticancer therapy, or at least 5 half-lives if the prior therapy is a single agent small-molecule therapeutic, and adequately recovered from the acute toxicities of any prior therapy, including neuropathy, to Grade ≤1.\n12. Non-pregnant and non-breastfeeding female:\n\n    1. Females of childbearing potential must agree to use effective contraception or abstinence without interruption from 28 days prior to starting nab-Sirolimus through 3 months after the last dose of nab-Sirolimus and have a negative serum pregnancy test (beta human chorionic gonadotropin \\[β-hCG\\]) result at screening and agree to ongoing pregnancy testing during the course of the study, and after the end of study treatment. A second form of birth control is required even if she has had a tubal ligation.\n    2. Sexual abstinence is considered a highly effective contraceptive method only if defined as refraining from heterosexual intercourse from 28 days prior to starting study medication throughout 3 months after last dose of study medication. The reliability of sexual abstinence should be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the patient.\n13. The patient understands and signs the informed consent.\n14. Willingness and ability to comply with scheduled visits, laboratory tests, and other study procedures.\n15. Patients with a known history of human immunodeficiency virus (HIV)infection are eligible if:\n\n    1. There has been no acquired immunodeficiency syndrome (AIDS)-defining opportunistic infection in 12 months prior to enrollment.\n    2. The patient has been receiving an antiretroviral therapy regimen for≥4 weeks and the HIV viral load is \\\u003C400 copies\u002FmL prior to enrollment.\n    3. Antiretroviral therapy regimen does not include strong cytochrome(CYP)3A4 inhibitors or inducers\n\nExclusion Criteria:\n\n1. Prior treatment with an mTOR inhibitor, including nab-sirolimus.\n2. Patients with known inactivating TSC1 or TSC2 alterations (based on tissue or liquid next generation sequencing \\[NGS\\]) unless the PRECISION 1 study (NCT05103358) has been closed to enrollment.\n3. Severe (Grade ≥3) ongoing infection requiring parenteral or oral anti-infective treatment, either ongoing or completed ≤7 days prior to enrollment.\n4. Patients with primary refractory disease (ie, those who have never achieved a complete or partial response to prior therapy) are not permitted on study.\n5. Patients with the following are excluded:\n\n   1. Known or suspected brain metastases.\n   2. Severe heart disease defined as unstable angina pectoris, New York Heart Association (NYHA) Class III or IV congestive heart failure, myocardial infarction ≤6 months prior to first study treatment, serious uncontrolled cardiac arrhythmia or any other clinically significant cardiac disease.\n   3. Severe lung disease defined as a diffusing capacity for carbon monoxide (DLCO) that is ≤50% of normal predicted value and\u002For an O2 saturation ≤88% at rest on room air (Note: spirometry and pulmonary function tests \\[PFTs\\] are not required to be performed unless clinically indicated).\n   4. Nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the treatment with the study therapy.\n   5. A history of malignancies other than the one under treatment unless the patient is disease-free for more than 5 years from completion of therapy administered with curative intent. Controlled non-melanoma skin cancers, carcinoma in situ of the cervix, resected incidental prostate cancer, certain low grade hematologic malignancies (eg, chronic lymphocytic leukemia \\[CLL\\], follicular lymphoma, etc), or other adequately treated carcinoma in situ may be eligible, after discussion with the Medical Monitor.\n   6. Uncontrolled hypertension (systolic blood pressure ≥160 mmHg and\u002For diastolic blood pressure ≥100 mmHg\n   7. Patients with history of interstitial lung disease and\u002For pneumonitis, or pulmonary hypertension.\n   8. Active hepatitis B and\u002For hepatitis C infection and detectable viral load despite antiviral therapy\n6. Required use of concomitant medications with strong CYP3A4 interactions (induction or inhibition) should be discontinued (strong inhibitors include ketoconazole, itraconazole, voriconazole, erythromycin, clarithromycin, telithromycin; strong inducers include rifampin and rifabutin). These agents must be discontinued prior to first dose of nab-sirolimus.",{"count":422,"type":21},29,[24],"A Phase 2 Multi-center Open-label Trial of nab-Sirolimus in Combination with Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer",[426,427,113,29,428,429],"Endometrial Cancer","Endometrioid Tumor","Recurrent Endometrial Carcinoma","Endometrioid Endometrial Cancer",[431,432,433,434,435,436,437,427,426,428,429],"nab-Sirolimus","FYARRO","Letrozole","Endometrial","Recurrent","ABI-009","Endometrial Carcinoma","2025-11-12",{"date":440,"type":39},"2025-11-13",{"date":442,"type":39},"2023-12-28",{"date":444,"type":21},"2027-06",{"name":446,"class":101},"Aadi Bioscience, Inc.",9,{"id":449,"slug":450,"hasResults":12,"nctId":451,"briefTitle":452,"officialTitle":453,"acronym":4,"eligibilityCriteria":454,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":455,"targetDuration":4,"studyType":22,"phases":457,"briefSummary":458,"conditions":459,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":462,"startDateStruct":463,"completionDateStruct":465,"leadSponsor":466,"locationsCount":467},"100490079","phase-1-dose-escalation-study-to-assess-safety-and-pharmacokinetics-of-nab-sirolimus-in-patients-with-locally-advanced-or-metastatic-solid-tumors-and-moderate-liver-impairment-100490079","NCT05661461","Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment","A Phase 1, Open-label, Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment","Inclusion Criteria:\n\n* For All Patients\n\n  1. Willing and able to provide informed consent and comply with protocol requirements for the duration of the study.\n  2. Male or female patients at least 18 years of age at the time of signing the informed consent form.\n  3. Histologically confirmed locally advanced or metastatic solid tumors that is measurable or non-measurable.\n  4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2.\n  5. Adequate hematologic counts:\n\n     * Absolute neutrophil count (ANC) ≥1.0 × 109 \u002FL (growth factor support allowed)\n     * Platelet count ≥75,000\u002Fmm 3 (75 × 10 9 \u002FL) (transfusion and\u002For growth factor support allowed)\n     * Hemoglobin ≥8.0 g\u002FdL (transfusion and\u002For growth factor support allowed)\n  6. Creatinine clearance ≥30 mL\u002Fmin as assessed by the Cockcroft-Gault equation:\n\n     Creatinine Clearance ≥30 = (140 - age) × (weight\\[kg\\] \u002F (72 x SCr\\[mL\u002Fmin\\]\\_ x 0.85, if female\n  7. Fasting serum triglyceride must be ≤300 mg\u002FdL; fasting serum cholesterol must be\n\n     ≤350 mg\u002FdL.\n  8. Male or non-pregnant and non-breastfeeding female:\n\n     * Females of child-bearing potential must agree to use highly effective contraception or abstinence without interruption from 28 days prior to first dose throughout 3 months after last dose and have a negative pregnancy test (urine or serum) result at screening and after the end of study treatment. A second form of birth control is required even if she has had a tubal ligation.\n     * Male patients must practice abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study and throughout 3 months after last dose. A second form of birth control is required even if he has undergone a successful vasectomy.\n  9. Minimum of 4 weeks since major surgery, completion of radiation, or completion of all prior systemic anticancer therapy, or at least 5 half-lives if the prior therapy is a single agent small-molecule therapeutic, and in either case adequately recovered from the acute toxicities of any prior therapy (including neuropathy) to Grade ≤1. For Patients with Normal Hepatic Function\n  10. Normal hepatic function (total bilirubin ≤ upper limit of normal \\[ULN\\] and aspartate aminotransferase \\[AST\\] ≤ULN). For Patients with Moderate Hepatic Impairment\n  11. Moderate hepatic impairment (total bilirubin 1.5-3.0 × ULN and any level of AST)\n\nExclusion Criteria:\n\n1. Received prior treatment with an mTOR inhibitor within 4 weeks prior to first dose.\n2. Patients who have any severe and\u002For uncontrolled medical or psychiatric conditions or other conditions that could affect their participation including:\n\n   1. Patients with meningeal carcinomatosis, leptomeningeal carcinomatosis, spinal cord compression, untreated brain metastases or symptomatic or unstable brain metastases. Note: Patients with stable brain metastases (defined as asymptomatic or no requirement for high-dose \\[defined as dexamethasone 10 mg daily or higher\\] or increasing dose of systemic corticosteroids) and without imminent need of radiation therapy are eligible. If applicable, patients must have completed brain radiation therapy and recovered adequately from any associated toxicity and\u002For complications prior to eligibility assessment. For patients who have received prior radiation therapy, post-treatment magnetic resonance imaging (MRI) scan should show no increase in brain lesion size\u002Fvolume.\n   2. Unstable angina pectoris, symptomatic congestive heart failure (New York Heart Association, NYHA class III or IV), myocardial infarction ≤6 months prior to first study treatment, serious uncontrolled cardiac arrhythmia or any other clinically significant cardiac disease.\n   3. Pre-existing severely impaired lung function. If a patient has a pre-existing pulmonary condition, eligible patients should have a spirometry and diffusing capacity for carbon monoxide (DLCO) that is \\>50% of the normal predicted value and\u002For O2 saturation that is \\>88% at rest on room air (Note: spirometry and pulmonary function tests \\[PFTs\\] not required to be performed unless clinically indicated).\n   4. Nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the treatment with the study therapy. Note, controlled non melanoma skin cancers, carcinoma in situ of the cervix, resected incidental prostate cancer, or other adequately treated carcinoma-in-situ may be eligible, after documented discussion with the Medical Monitor.\n   5. Uncontrolled hypertension (systolic blood pressure ≥160 mmHg and\u002For diastolic blood pressure ≥100 mmHg).\n   6. Patients with history of interstitial lung disease and\u002For pneumonitis, or pulmonary hypertension.\n   7. Individuals with known human immunodeficiency virus (HIV) infection are excluded from this study as combination antiretroviral therapy could potentially result in significant pharmacokinetic interactions. In addition, these individuals are at increased risk of serious infections due to the immunosuppressive effects of mTOR inhibition.\n   8. Active Hepatitis B or Hepatitis C, with detectable viral load. Note: A detailed assessment of Hepatitis B\u002FC medical history and risk factors must be done at screening for all patients.\n3. Have active severe (Grade ≥3) infection requiring intravenous (IV) antibiotics (contact medical monitor for clarification).\n4. High-dose systemic corticosteroids (\\>10 mg of prednisone or its equivalent) are not permitted within 2 weeks of first dose. However, inhaled, intranasal, intra articular, and topical steroids are allowed.\n5. Have a history of Gilbert's disease.\n6. Any condition that in the opinion of the Investigator would place the patient at an unacceptable risk or cause the patient to be unlikely to fully participate or comply with study procedures.\n\n   For Patients with Moderate Hepatic Impairment\n7. Had a clinical exacerbation of liver disease within the 2-week period prior to first dose (ie, abdominal pain, nausea, vomiting, anorexia, or fever).\n8. Have clinically demonstrable, tense ascites.\n9. Had evidence of acute viral hepatitis within 1 month prior to first dose.\n10. Have evidence of hepatorenal syndrome.\n11. Have a transjugular intrahepatic portosystemic shunt.\n12. Have active stage 3 or 4 encephalopathy.",{"count":456,"type":21},28,[247],"This is a phase 1, multi-center, open-label, dose-escalation study of nab-sirolimus in adult patients with locally advanced or metastatic solid tumors and moderate hepatic impairment or normal hepatic function.",[460,29,461],"Tumor, Solid","Advanced Solid Tumor",{"date":440,"type":39},{"date":464,"type":39},"2022-11-23",{"date":390,"type":21},{"name":446,"class":101},2,{"id":469,"slug":470,"hasResults":12,"nctId":471,"briefTitle":472,"officialTitle":473,"acronym":474,"eligibilityCriteria":475,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":476,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":478,"conditions":479,"keywords":482,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":487,"lastUpdatePostDateStruct":488,"startDateStruct":490,"completionDateStruct":491,"leadSponsor":493,"locationsCount":494},"100604280","performance-indicators-and-impact-on-the-care-pathway-of-sequencing-on-the-seqoia-and-auragen-seqogen-platforms-for-oncology-patients-100604280","NCT07147465","Performance Indicators and Impact on the Care Pathway of Sequencing on the SeqOIA and AURAGEN (Seqogen) Platforms for Oncology Patients","Indicateurs de Performance et Impact Sur le Parcours de Soins du Séquençage Sur Les Plateformes Seqoia et Auragen (Seqogen) Pour Les Patients en Oncologie","SONCO","Inclusion Criteria:\n\n* Patients diagnosed with cancer and referred for high-throughput sequencing\n* Sequencing pre-indication validated: Patients for whom the pre-indication for sequencing the genome, exome, and RNA has been validated by the upstream RCP (Multidisciplinary Tumor Board) since January 1, 2021.\n\nConsent for data reuse: Patients who have agreed to the reuse of their medical and genomic data for research purposes and have not opposed this use.\n\nExclusion Criteria:\n\n* Opposition to data reuse, unvalidated upstream RCP",{"count":477,"type":21},3149,"As part of the French Genomic Medicine Plan 2025 (FGM), the SeqOIA and AURAGEN platforms were selected to perform high-throughput genomic sequencing.\n\nThe SONCO (Sequencing Oncology Cohort) project combines their medical and economic evaluations into a single national cohort. Its objective is to assess the impact of genomic sequencing on care pathways and treatment recommendations by collecting indicators related to quality, turnaround time, and patient information. Clinical data are gathered from molecular tumor board reports (via SPICE and HYGEN) and from hospital medical records.\n\nThis cohort is intended to support public health decision-making and help anticipate the organization of future genomic platforms.",[113,480,29,481],"NGS","RARE DISEASE",[301,483,484,485,486],"genomic medecine","cancer","rare diseases","next-generation sequencing","2025-08-22",{"date":489,"type":39},"2025-08-29",{"date":117,"type":39},{"date":492,"type":21},"2026-09-30",{"name":375,"class":46},3,{"id":496,"slug":497,"hasResults":12,"nctId":498,"briefTitle":499,"officialTitle":500,"acronym":4,"eligibilityCriteria":501,"healthyVolunteers":54,"sex":17,"minAge":502,"maxAge":128,"enrollmentInfo":503,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":505,"conditions":506,"keywords":507,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":511,"lastUpdatePostDateStruct":512,"startDateStruct":514,"completionDateStruct":516,"leadSponsor":518,"locationsCount":520},"100576913","ai-driven-cancer-diagnosis-and-prediction-with-ehr-100576913","NCT06791473","AI-Driven Cancer Diagnosis and Prediction With EHR","AI-Based Cancer Diagnosis and Prediction Using Electronic Health Records","Inclusion Criteria:\n\n1、Patients with comprehensive electronic health records (EHRs), including medical history, laboratory test results, imaging data, and genetic data (if available).\n\n2\\. Individuals without severe cognitive impairments or conditions that would prevent them from providing informed consent or participating in the study.\n\n3\\. Parents or guardians must provide informed consent for minors, while adult participants must provide informed consent for themselves.\n\nExclusion Criteria:\n\n1. Patients with incomplete or missing key electronic health record data or insufficient follow-up data.\n2. Individuals with severe cognitive disorders or other terminal illnesses that would prevent meaningful participation.\n3. Pregnant women (although pediatric cancers are being considered, pregnant women would be excluded for safety reasons).","0 Years",{"count":504,"type":21},1000000,"This is a multi-center, clinical study designed to evaluate the application and effectiveness of an AI-assisted predictive model for identifying and diagnosing cancer, leveraging multimodal health data.",[29],[508,509,510],"tumor","Early Disease Prediction","AI-Assisted Diagnosis","2025-07-25",{"date":513,"type":39},"2025-07-30",{"date":515,"type":39},"2025-01-19",{"date":517,"type":21},"2025-10-01",{"name":519,"class":46},"The Eye Hospital of Wenzhou Medical University",7,{"id":522,"slug":523,"hasResults":12,"nctId":524,"briefTitle":525,"officialTitle":526,"acronym":4,"eligibilityCriteria":527,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":528,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":530,"conditions":531,"keywords":534,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":537,"lastUpdatePostDateStruct":538,"startDateStruct":540,"completionDateStruct":542,"leadSponsor":544,"locationsCount":494},"100598453","study-of-peripheral-blood-chi3l1-to-predict-tumor-response-to-radiotherapy-100598453","NCT07071688","Study of Peripheral Blood CHI3L1 to Predict Tumor Response to Radiotherapy","Predictive Value of Peripheral Blood CHI3L1 for Tumor Radiosensitivity: A Prospective and Retrospective Cohort Study","Inclusion Criteria:\n\n* Voluntarily signed informed consent form;\n* Age ≥ 18 years;\n* No restrictions on sex;\n* Histologically confirmed diagnosis of one of the following malignant tumors: nasopharyngeal carcinoma, head and neck cancer, lung cancer, breast cancer, gastric cancer, colorectal cancer, glioma, esophageal cancer, liver cancer, cholangiocarcinoma, cervical cancer, prostate cancer, or bladder cancer;\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.\n\nExclusion Criteria:\n\n* Patients with any serious comorbidities that may pose an unacceptable risk or adversely affect compliance with the study protocol. Examples include unstable heart disease requiring treatment, chronic hepatitis, renal disease with poor clinical status, uncontrolled diabetes mellitus (fasting blood glucose \\> 1.5 × ULN), or psychiatric disorders.\n* Deemed unsuitable for participation in the study at the discretion of the investigators.",{"count":529,"type":21},338,"Radiotherapy is an important treatment for many malignant tumors. However, radioresistance remains a major cause of treatment failure, often leading to tumor recurrence or progression. As a key factor affecting prognosis, radioresistance currently lacks reliable methods for identifying high-risk individuals before treatment. Liquid biopsy, as a non-invasive and dynamic monitoring tool, offers unique advantages for real-time assessment. Previous studies from our group have shown that peripheral blood levels of CHI3L1 are significantly elevated in patients with radioresistant tumors and may serve as a predictive biomarker for radiotherapy sensitivity. This study aims to conduct a multicenter, bidirectional cohort study to systematically evaluate the predictive value of peripheral blood CHI3L1 as a pan-cancer biomarker for tumor response to radiotherapy.",[29,532,533],"Radiotherapy","Biomarker",[29,532,535,536],"Radioresistance","CHI3L1","2025-07-08",{"date":539,"type":39},"2025-07-17",{"date":541,"type":21},"2025-07-20",{"date":543,"type":21},"2028-12-31",{"name":545,"class":46},"Nanfang Hospital, Southern Medical University",{"id":547,"slug":548,"hasResults":12,"nctId":549,"briefTitle":550,"officialTitle":550,"acronym":4,"eligibilityCriteria":551,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":552,"enrollmentInfo":553,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":555,"conditions":556,"keywords":558,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":562,"lastUpdatePostDateStruct":563,"startDateStruct":565,"completionDateStruct":567,"leadSponsor":568,"locationsCount":47},"100589571","exploring-the-clinical-application-value-of-caix-targeted-pet-imaging-in-renal-cancer-patients-100589571","NCT06956144","Exploring the Clinical Application Value of CAIX-Targeted PET Imaging in Renal Cancer Patients","Inclusion Criteria:\n\n1. Voluntary participation with the patient or their legal representative able to sign the informed consent form.\n2. Adult patients (age between 18 and 75 years), regardless of gender.\n3. Patients with clinically suspected or confirmed primary kidney cancer (supporting evidence includes imaging data and histopathological examination; specific case types include clear cell carcinoma, papillary renal cell carcinoma, and chromophobe renal cell carcinoma) who agree to undergo histopathological examination (if not already performed prior to imaging).\n4. Patients must have undergone enhanced CT, with the enhanced CT examination conducted within 2 weeks prior to enrollment.\n5. ECOG performance status score of 0-3.\n6. Laboratory parameters must meet the following criteria:\n\n   1. ALT and AST must not exceed 3 times the upper limit of normal; BUN and creatinine must not exceed 1.5 times the upper limit of normal.\n   2. Hematological parameters: 2 x 10\\^9\u002FL ≤ WBC ≤ 2 x 10\\^10\u002FL, PLT ≥ 80 x 10\\^9\u002FL, Hb ≥ 80 g\u002FL.\n7. Willing and able to comply with follow-up visits, treatment plans, and related laboratory examinations.\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding patients (all women of childbearing age must undergo pregnancy testing during the screening phase, such as a urine pregnancy test or blood HCG test, to confirm their pregnancy status).\n2. Patients or their legal representatives who are unable or unwilling to sign the informed consent form.\n3. Acute systemic diseases and electrolyte imbalances.\n4. Patients unable to complete the PET\u002FCT examination (including those unable to lie flat, those with claustrophobia, radiophobia, etc.).\n5. Researchers believe that the patient has poor compliance or has other factors making them unsuitable for participation in this study.","74 Years",{"count":554,"type":21},113,"To evaluate the efficacy of targeted CAIX-specific probe PET imaging in the diagnosis and staging of kidney cancer, as well as to assess its role in prognosis prediction and treatment evaluation for kidney cancer.",[29,557],"Carbonic Anhydrase IX",[559,560,561,136],"PET","CAIX","Renal Cancer","2025-05-27",{"date":564,"type":39},"2025-05-29",{"date":566,"type":39},"2025-05-09",{"date":492,"type":21},{"name":145,"class":46},{"id":570,"slug":571,"hasResults":12,"nctId":572,"briefTitle":573,"officialTitle":573,"acronym":4,"eligibilityCriteria":574,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":243,"enrollmentInfo":575,"targetDuration":577,"studyType":57,"phases":4,"briefSummary":578,"conditions":579,"keywords":583,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":585,"lastUpdatePostDateStruct":586,"startDateStruct":588,"completionDateStruct":589,"leadSponsor":591,"locationsCount":47},"100571856","glucagon-like-peptide-1-receptor-petct-in-glp-1r-related-disease-100571856","NCT06725693","Glucagon-like Peptide-1 Receptor PET\u002FCT in GLP-1R Related Disease","Inclusion Criteria:\n\n\\- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled Exendin 4 PET\u002FCT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n\\- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.",{"count":576,"type":21},500,"7 Days","To evaluate the potential usefulness of 68Ga\u002F18F-Exendin 4 positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various GLP-1R-related disease patients.",[580,29,581,582],"GLP1-R-related Disease","Insulinoma","Positron Emission Tomography",[135,584],"GLP1-R","2025-02-07",{"date":587,"type":39},"2025-02-11",{"date":342,"type":39},{"date":590,"type":21},"2027-11-01",{"name":592,"class":46},"Tianjin Medical University",{"id":594,"slug":595,"hasResults":12,"nctId":596,"briefTitle":597,"officialTitle":597,"acronym":4,"eligibilityCriteria":598,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":243,"enrollmentInfo":599,"targetDuration":577,"studyType":57,"phases":4,"briefSummary":600,"conditions":601,"keywords":604,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":585,"lastUpdatePostDateStruct":608,"startDateStruct":609,"completionDateStruct":610,"leadSponsor":612,"locationsCount":47},"100569185","somatostatin-receptor-petct-in-sstr-related-disease-patients-100569185","NCT06690957","Somatostatin Receptor PET\u002FCT in SSTR-Related Disease Patients","Inclusion Criteria:\n\n\\- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled SSTR PET\u002FCT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n\\- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.",{"count":576,"type":21},"To evaluate the potential usefulness of 68Ga\u002F18F-TATE\u002FJR11\u002FLM3 positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various SSTR-related disease patients.",[602,29,582,603],"SSTR-related Disease","Metastasis",[135,605,606,607],"SSTR","Angonist","Antagonist",{"date":587,"type":39},{"date":342,"type":39},{"date":611,"type":21},"2027-10-01",{"name":592,"class":46},{"id":614,"slug":615,"hasResults":12,"nctId":616,"briefTitle":617,"officialTitle":617,"acronym":4,"eligibilityCriteria":618,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":243,"enrollmentInfo":619,"targetDuration":4,"studyType":22,"phases":621,"briefSummary":622,"conditions":623,"keywords":625,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":585,"lastUpdatePostDateStruct":629,"startDateStruct":630,"completionDateStruct":632,"leadSponsor":633,"locationsCount":47},"100569168","chemokine-receptor-4-petct-imaging-of-cxcr4-related-diseases-100569168","NCT06690736","Chemokine Receptor 4 PET\u002FCT Imaging of CXCR4-Related Diseases","Inclusion Criteria:\n\n* suspected or confirmed untreated Lymphoproliferative and other CXCR4-related diseases patients\n* 18F-FDG PET\u002FCT within two weeks\n* signed written consent.\n\nExclusion Criteria:\n\n* pregnancy\n* breastfeeding\n* known allergy against Pentixafor",{"count":620,"type":21},200,[81],"To evaluate the potential usefulness of 68Ga\u002F18F-Pentixafor\u002FPentixather positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various CXCR4-related disease patients.",[624,29,582,603],"CXCR4-related Disease",[135,626,627,628],"Chemokine receptor 4","Pentixafor","Pentixather",{"date":587,"type":39},{"date":631,"type":39},"2022-03-01",{"date":611,"type":21},{"name":592,"class":46},{"id":635,"slug":636,"hasResults":12,"nctId":637,"briefTitle":638,"officialTitle":638,"acronym":4,"eligibilityCriteria":639,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":243,"enrollmentInfo":640,"targetDuration":577,"studyType":57,"phases":4,"briefSummary":641,"conditions":642,"keywords":644,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":585,"lastUpdatePostDateStruct":646,"startDateStruct":647,"completionDateStruct":648,"leadSponsor":649,"locationsCount":47},"100568963","fapi-petct-in-various-fap-related-disease-patients-100568963","NCT06688071","FAPI PET\u002FCT in Various FAP-Related Disease Patients","Inclusion Criteria:\n\n* (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled FAPI PET\u002FCT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n* (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.",{"count":576,"type":21},"To evaluate the potential usefulness of 68Ga\u002F18F-FAPI positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various FAP-related disease patients.",[643,29,582,603],"FAP-related Disease",[135,252,645],"FAPI",{"date":587,"type":39},{"date":631,"type":39},{"date":611,"type":21},{"name":592,"class":46}]